JP2005516907A - 霊長類ｉｆｎ−ガンマ結合分子の使用 - Google Patents

霊長類ｉｆｎ−ガンマ結合分子の使用 Download PDF

Info

Publication number
JP2005516907A
JP2005516907A JP2003547457A JP2003547457A JP2005516907A JP 2005516907 A JP2005516907 A JP 2005516907A JP 2003547457 A JP2003547457 A JP 2003547457A JP 2003547457 A JP2003547457 A JP 2003547457A JP 2005516907 A JP2005516907 A JP 2005516907A
Authority
JP
Japan
Prior art keywords
ifn
antibody
primate
fragment
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003547457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005516907A5 (enExample
Inventor
カトリーン・ローレ
マリー−アンジュ・ビュイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Innogenetics NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics NV SA filed Critical Innogenetics NV SA
Publication of JP2005516907A publication Critical patent/JP2005516907A/ja
Publication of JP2005516907A5 publication Critical patent/JP2005516907A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003547457A 2001-11-30 2002-11-27 霊長類ｉｆｎ−ガンマ結合分子の使用 Pending JP2005516907A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01870266 2001-11-30
US34149901P 2001-12-17 2001-12-17
EP02447043 2002-03-25
PCT/EP2002/013358 WO2003046008A1 (en) 2001-11-30 2002-11-27 Therapeutic use of antibodies and fragments thereof binding primate ifn-gamma

Publications (2)

Publication Number Publication Date
JP2005516907A true JP2005516907A (ja) 2005-06-09
JP2005516907A5 JP2005516907A5 (enExample) 2006-01-05

Family

ID=56290362

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003547457A Pending JP2005516907A (ja) 2001-11-30 2002-11-27 霊長類ｉｆｎ−ガンマ結合分子の使用

Country Status (6)

Country Link
US (1) US20030211103A1 (enExample)
EP (1) EP1463761A1 (enExample)
JP (1) JP2005516907A (enExample)
AU (1) AU2002365514A1 (enExample)
CA (1) CA2467647A1 (enExample)
WO (1) WO2003046008A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4673068B2 (ja) * 2005-01-19 2011-04-20 独立行政法人科学技術振興機構 Ｔｈ１型アレルギー疾患治療用組成物
ES2428876T3 (es) 2006-09-12 2013-11-12 F. Hoffmann-La Roche Ag Ensayo de anticuerpo antifármaco
BRPI0719912A2 (pt) * 2006-12-06 2014-03-04 Medimmune Llc Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
AU2008247395A1 (en) * 2007-05-03 2008-11-13 Medimmune, Llc Auto-antibody markers of autoimmune disease
US20100261172A1 (en) * 2007-05-03 2010-10-14 Medimmune, Llc Interferon alpha-induced pharmacodynamic markers
MX2020005790A (es) 2018-01-19 2020-10-28 Generation Bio Co Vectores de adn de extremo cerrado que pueden obtenerse de síntesis libre de células y un proceso para obtener vectores de ceadn.
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN114747535B (zh) * 2022-03-29 2024-03-22 华南理工大学 一种急性脓毒症非人灵长类动物模型及其构建方法
US20250334587A1 (en) * 2024-04-26 2025-10-30 Swedish Orphan Biovitrum Ag Use of emapalumab for treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999009055A2 (en) * 1997-08-18 1999-02-25 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders

Also Published As

Publication number Publication date
CA2467647A1 (en) 2003-06-05
US20030211103A1 (en) 2003-11-13
EP1463761A1 (en) 2004-10-06
WO2003046008A1 (en) 2003-06-05
WO2003046008A9 (en) 2004-05-06
AU2002365514A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
US8623355B2 (en) Methods for suppressing acute rejection of a heart transplant
RU2446826C2 (ru) Агенты для подавления повреждения трансплантированных островков после трансплантации островков
RU2490025C2 (ru) Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
KR101762966B1 (ko) 항체 제제
RU2286351C2 (ru) Антитела к человеческому il-1бета
AU2008208321B2 (en) Chronic rejection inhibitor
US10202449B2 (en) Cachexia treatment
KR101681331B1 (ko) 치료를 위한 ｇｍ-ｃｓｆ 및 ｉｌ-17의 억제제
JPH08505365A (ja) 自己免疫疾患および炎症性疾患の治療
JP2001501607A (ja) 免疫調節のためのｃｄ４５ｒ白血球抗原に対する抗体の利用
CN1750844A (zh) 用于预防和治疗与局部缺血－再灌注损伤相关的组织损伤的方法
JP6245622B2 (ja) Ｉｌ−１８と分子標的抗体とを併用する癌治療薬
US9988447B2 (en) Treatment of diabetes
US20120201821A1 (en) Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
KR20190066067A (ko) 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
US12209124B2 (en) Anti-IL-17A antibody and use thereof
CN113194996A (zh) 克拉扎珠单抗用于治疗慢性抗体介导的器官移植物排斥反应
EP3362088B1 (en) An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction
CA2744670C (en) A b cell depleting agent for the treatment of atherosclerosis
BR112020025504A2 (pt) Anticorpo que induz a imunotolerância, linfócito induzido, e agente de terapia celular método terapêutico usando o linfócito induzido
KR20230142834A (ko) 항-cd38 항체 및 이의 용도
US20040247598A1 (en) Use of il-18 inhibitors in hypersensitivity disorders
RU2816994C2 (ru) Антитела к bcma, содержащие только тяжелую цепь
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050707

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090310